前列腺癌骨转移内分泌治疗合并贫血的临床观察

薛鹏; 王祥波; 涂传全; 张志刚; 赵海岩; 杨光天; 杨文发

前列腺癌骨转移内分泌治疗合并贫血的临床观察

- 连云港市第一人民医院泌尿外科(江苏连云港, 222000)

详细信息

通讯作者: 薛鹏,E-mail:xuepsun@126.com

中图分类号: R737.25

收稿日期: 2012-04-02

Clinical observation of anemia in patients with prostatic carcinoma osseous metastasis accepted hormonal therapy

- Department of Urology, Lianyungang First People's Hospital, Lianyungang, Jiangsu, 222000, China

More Information

Corresponding author: XUE Peng, E-mail: xuepsun@126.com

Received Date: 02 April 2012

摘要

摘要: 目的：观察前列腺癌骨转移及接受内分泌治疗对患者造血功能的影响。方法：对38例前列腺癌骨转移患者采用内分泌治疗（联合雄激素阻断，睾丸切除+氟他胺，250 mg/次，3次/d）。分别于治疗前及治疗后1、3、6个月检查血红蛋白（Hb）及红细胞压积（Ht），5例患者行骨髓穿刺细胞学检查。结果：前列腺癌骨转移合并贫血患者27例（71%），血小板减少7例，5例骨穿患者除1例骨髓"干抽"外，余4例骨髓涂片可见肿瘤细胞分布。治疗前及治疗后1、3、6个月Hb分别为（104±16）、（89±14）、（84±15）、（81±14） g/L；Ht分别为（0.321±0.035）、（0.292±0.036），（0.284±0.038），（0.281±0.036）。治疗前后相比均差异有统计学意义（P<0.05）。结论：前列腺癌骨转移严重影响患者造血功能，内分泌治疗可导致或加重患者贫血。
- 前列腺癌 /
- 骨转移 /
- 内分泌治疗 /
- 贫血
Abstract: Objective: To investigate the influence of prostatic carcinoma osseous metastasis and hormonal therapy on the haematogenesis function. Method: Thirty-eight patients with prostatic carcinoma osseous metastasis were treated by combined androgen block(orchiectomy and flutamide 250mg,tid).Complete blood counts were detected before initiation and after 1、3 and 6 months of therapy, and 5 cases accepted bone marrow aspiration cytological examination. Result: There were 71%(27/38) patients with anemia, 7cases with thrombocytopenia, and tumor cells were found in the film preparation of 4 cases in the 5 patients accepted bone marrow aspiration cytological examination.Marrow "dry-draw"(marrow couldn't be got when bone marrow aspiration being done)took place in 1 case. Hb level decreased from a mean baseline of (104±16) g/L to(89±14) g/L,(84±15) g/L,(81±14) g/L after 1、3 and 6 months of therapy.Ht decreased from a mean baseline of (0.321±0.035) to (0.292±0.036),(0.284±0.038),(0.281±0.036).The differences between before and after treatment were significant(P<0.05). Conclusion: There is great influence of prostatic carcinoma osseous metastasis on the haematogenesis function, and hormonal therapy can also cause anemia or even deteriorate it.
- prostatic carcinoma /
- osseous metastasis /
- hormonal therapy /
- anemia

HTML全文

参考文献(9)

[1]	BUBENDORF L,SCHOPFER A,WAGNER U,et al. Metastatic patterns of prostate cancer:an autopsy study of 1589 patients[J]. Hum Pathol,2000,31(5):578-588.
[2]	李鸣.前列腺癌热点问题评书[J].现代泌尿生殖肿瘤杂志,2011,3(3),129-131.
[3]	DUNN A, CARTER J, CARTER H.Anemia at the end of life:prevalence,significance,and causes in patients receiving palliative care[J]. J Pain Symptom Manage, 2003,26(6):1132-1139.
[4]	BEER T M,TANGEN C M,BLAND L B,et al. Prognostic value of anemia in newly diagnosed metastatic prostate cancer:a multivariate analysis of southwest oncology group study 8894[J].J Urol,2004,172(6 Pt 1):2213-2217.
[5]	ARANGO O,LORENTE J A,BIELSA O,et al. Anemia and neoadjuvant hormone therapy in radial surgery of localized cancer of the prostate[J].Actas Urol Esp, 2001,25(2):105-109.
[6]	LI X Q,LI X H,HONG F W,et al.Anemia in patients on combined androgen block therapy for prostate cancer[J].Asian J Androl,2004,6(4):383-384.
[7]	CHOO R,CHANDER S,DANJOUX C,et al. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients[J]? Can J Urol,2005,12(1):2547-2552.
[8]	YUN H K,SHIN M G,BO D,et al. Laboratory evaluation of bone marrow metastasis:single institute study[J].Korean J Lab Med, 2007,27(2):96-101.
[9]	周铁,许传亮,孙颖浩. 促红细胞生成素受体在前列腺癌组织中的表达及意义[J]. 中华泌尿外科杂志,2007,28(12):832-834.